Cohance Lifesciences: Can a recovery justify its valuation?
Cohance Lifesciences business numbers have been hard to stomach. FY26 revenue fell 13% and adjusted EBITDA nearly halved. Q1 FY27 revenue fell 23%, adjusted EBITDA margin dropped to 2.2%, and the company reported a net loss of Rs 45 crore. At around Rs 479 per share, Cohance’s market capitalisation is approximately Rs 17,000 crore, and […]
Cohance Lifesciences business numbers have been hard to stomach. FY26 revenue fell 13% and adjusted EBITDA nearly halved. Q1 FY27 revenue fell 23%, adjusted EBITDA margin dropped to 2.2%, and the company reported a net loss of Rs 45 crore. At around Rs 479 per share, Cohance’s market capitalisation is approximately Rs 17,000 crore, and […]
What's Your Reaction?
